Biphasic Ventilation Airway Management Clinical Trial

Intubation Clinical Trial

— BVAM  

Official title:

Is Biphasic Ventilation Airway Management Utilizing Biphasic Cuirass Ventilation a Feasible Method to Provide Ventilation During the Apneic Phase for Patients Undergoing Emergent Rapid Sequence Intubation in the Emergency Department?

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03042598
• Other study ID #: EM 2016.05
• Status: Recruiting
• Phase: N/A
• First received: November 2, 2016
• Last updated: February 2, 2017
• Start date: January 14, 2017
• Est. completion date: April 2017

Study information

• Verified date: February 2017
• Source: University Medical Center of Southern Nevada
• Contact: David E Slattery, MD
• Phone: 702-561-6260
• Email: dslatts[@]me.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Investigators intend to determine if the use of Biphasic Cuirass Ventilation (BCV) improves patient safety (avoiding hypoxia) during emergency rapid sequence intubation .

Description:

Methods/ Interventions:

Patients who are deemed to meet inclusion criteria and none of the exclusion criteria will be preoxygenated by any of the acceptable standard preoxygenation strategies (non-rebreather face mask, noninvasive positive pressure ventilation, etc.) . Patients will be placed and maintained on continuous 3-lead cardiac, automatic blood pressure, pulse oximeter, and waveform capnography monitoring for the duration of the procedure. Prior to induction, and during the pre oxygenation phase, subjects will be placed on the Biphasic Cuirass Ventilation (BCV) device per the manufacturer's guidelines. After adequate preoxygenation has been achieved (as determined by the treating emergency physician), the BCV assisted ventilations will be maintained and standard of care intubation procedures including apenic oxygenation if ordered by attending emergency physician will be utilized. BCV will be discontinued upon confirmation of proper tracheal intubation by waveform capnography.

Safety The BCV device covers the anterior chest wall, and therefore, it cannot be in place if CPR is needed. Therefore, all patients in cardiac arrest will be excluded. Investigators will be excluding patients with a pacemaker or central line which impairs the ability of the Curiass shell to secure on the anterior chest. Finally, patients with a history of valvular heart disease will be excluded. The protocol directs the device be applied during the normal preoxygenation period (~within that 3-5 minute period of time prior to the administration of the induction and paralytic medications). There are no other known side effects of this device. There is a potential for the device application to delay the intubation attempt; however, it is not known whether delaying intubation ,while augmenting a patient's breathing with the BCV device, negatively impacts the patient's condition. The data collection form explicitly asks the intubating physician thinks that the device delayed the intubation attempt in any way. The data collection form also tracks all of the relevant time milestones. Both of these items will be reviewed periodically during the study as safety endpoints by the data monitoring committee and will be included in the manuscript results.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: April 2017
• Est. primary completion date: April 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients who present to the adult emergency department and require emergency intubation.

• Patient's primary language is English.

Exclusion Criteria:

• Cardiac arrest.

• Attending provider excludes patient as being at high risk for cardiac arrest or for any other reason.

• Patients who are known or reported to be pregnant pre-procedure.

• Patients in the custody of law enforcement.

• Inability to pre-oxygenate patient to an SPO2 equal to or greater than 95 percent prior to induction.

• Morbidly or Extremely obese patients defined by the NIH as BMI greater than 40.

• History of valvular heart disease.

• Presence of subclavian central line or pacemaker which impairs ability of shell to seal.

Related Conditions & MeSH terms

• Intubation

Intervention

Device:
• Biphasic Cuirass Ventilation
The RTX Respirator will be applied to the patient's chest to provide non-invasive ventilatory support using a Biphasic Cuirass Ventilation technology to increase the safe apnic period during intubation.

Locations

Country	Name	City	State
United States	University Medical Center of Southern Nevada	Las Vegas	Nevada

Sponsors (1)

Lead Sponsor	Collaborator
University Medical Center of Southern Nevada

Country where clinical trial is conducted

United States, 

References & Publications (8)

Benumof JL, Dagg R, Benumof R. Critical hemoglobin desaturation will occur before return to an unparalyzed state following 1 mg/kg intravenous succinylcholine. Anesthesiology. 1997 Oct;87(4):979-82. — View Citation

Bodily JB, Webb HR, Weiss SJ, Braude DA. Incidence and Duration of Continuously Measured Oxygen Desaturation During Emergency Department Intubation. Ann Emerg Med. 2016 Mar;67(3):389-95. doi: 10.1016/j.annemergmed.2015.06.006. — View Citation

Brimacombe J, Keller C. Who is at increased risk of aspiration? Br J Anaesth. 2005 Feb;94(2):251; author reply 251-2. — View Citation

Corrado A, Gorini M, Melej R, Baglioni S, Mollica C, Villella G, Consigli GF, Dottorini M, Bigioni D, Toschi M, Eslami A. Iron lung versus mask ventilation in acute exacerbation of COPD: a randomised crossover study. Intensive Care Med. 2009 Apr;35(4):648-55. doi: 10.1007/s00134-008-1352-9. — View Citation

Kamine TH, Papavassiliou E, Schneider BE. Effect of abdominal insufflation for laparoscopy on intracranial pressure. JAMA Surg. 2014 Apr;149(4):380-2. doi: 10.1001/jamasurg.2013.3024. — View Citation

Li J, Murphy-Lavoie H, Bugas C, Martinez J, Preston C. Complications of emergency intubation with and without paralysis. Am J Emerg Med. 1999 Mar;17(2):141-3. — View Citation

Sakles JC, Chiu S, Mosier J, Walker C, Stolz U. The importance of first pass success when performing orotracheal intubation in the emergency department. Acad Emerg Med. 2013 Jan;20(1):71-8. doi: 10.1111/acem.12055. — View Citation

Weingart SD, Levitan RM. Preoxygenation and prevention of desaturation during emergency airway management. Ann Emerg Med. 2012 Mar;59(3):165-75.e1. doi: 10.1016/j.annemergmed.2011.10.002. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite Primary Endpoint is the composite prevalence of any desaturation defined as SPO2 < 95% or Bradycardia, HR <60 beats per minute sustained for at least 30 seconds	The primary outcome measure is the composite prevalence of any desaturation defined as SPO2 < 95% or Bradycardia, HR <60 beats per minute sustained for at least 30 seconds, during and in the immediate post intubation (5 minutes after tracheal intubation is confirmed) period.	0 to 5 minutes after intubation
Secondary	Prevalence of post-paralytic Bag valve mask use	Prevalence of post-paralytic administration bag valve mask ventilation in subjects enrolled into trial. We will describe this with a percentage and surrounding 95% confidence interval. This outcome reflects the potential need for ventilation during and around the intubation attempt. Our hypothesis is that BCV will eliminate the physiologic need for BVM rescue ventilation between the time paralytics are administered until the endotracheal tube is confirmed to be properly placed.	Time from paralytics administered until proper endotracheal tube placement is confirmed.
Secondary	Waveform capnography pattern	The investigators will describe the pattern of waveform capnography as measured by the research nasal capnography monitor. The waveform capnography trends will be represented graphically as continuous data for each subject over time to reflect the patterns observed from baseline until endotracheal tube is successfully placed in the trachea.	Baseline to 30 minutes after intubation
Secondary	Change in End-Tidal Carbon Dioxide (ETCO2) values	We will describe the change in the mean +/- SEM and median +/- IQR ETCO2 values as measured from baseline to intubation.	Period of time from acquiring baseline ETCO2 value to successful intubation.
Secondary	Blood Pressure response to the BCV device	Investigators will describe the physiologic response to the BCV device by graphically representing each subject's systolic, diastolic, and mean arterial pressures (mmHG) in serial 5 minute measurements obtained from the immediate pre-application of the BCV device period until 30 minutes after intubation is complete. Unit of measure= mmHG	Baseline vital signs to 30 Minutes after intubation
Secondary	SpO2 response to pre-oxygenation attempts BCV application	Investigators will describe the physiologic response to the BCV device by graphically representing each subject's oxygen saturation measurements obtained from the immediate pre-application of the BCV device period until 30 minutes after intubation is complete. Unit of measure= % oxygen saturation	Baseline vital signs to 30 Minutes after intubation